Spinal cord stimulation in peripheral vascular disease

RC TALLIS,* LS ILLIS, EM SEDGWICK, C HARDWIDGE, JS GARFIELD
From the Wessex Neurological Centre and the Southampton General Hospital, Southampton, UK

SUMMARY  The results of ten patients with severe, intractable symptoms of arterial disease receiv-
ing spinal cord stimulation are reported. Six out of ten patients showed clinical improvement.
Three of five patients with severe rest pain obtained complete or very marked relief and one of
two patients with moderate rest pain in the legs obtained complete relief. The mean claudication
distance in the ten patients increased from 65 to 212 metres during epidural stimulation of the
spinal cord. Exercise tolerance as measured on a bicycle ergometer increased by 61%. These
changes were associated with small increases in cutaneous and muscle blood flow. In those
patients who responded clinically, the improvements seen were maintained as long as spinal cord
stimulation was continued. There was no clinical response to transcutaneous (placebo) stimula-
tion and four patients did not respond in any way to spinal cord stimulation. The improvements
seen are unlikely to be due to either the natural history of the disease or to a placebo effect. The
effect is probably due to antidromic stimulation of the central processes of the first order sensory
neurons. It is suggested on the basis of animal studies that this effect may be mediated by release
of prostaglandins as well as indirectly via pain relief.

Spinal cord stimulation was first introduced into clinical practice for the treatment of intractable pain.¹
Since Cook & Weinstein² reported its therapeutic benefit in multiple sclerosis, it has also been used in
the rehabilitation of patients with chronic neurological disease. The employment of epidural electrodes³
makes spinal cord stimulation a relatively minor procedure since the electrodes can be introduced via
an epidural needle. Most workers are agreed that the main benefits of spinal cord stimulation are in
bladder function⁴-⁶ and it is these changes that have been most carefully documented.

Less attention has been paid to other influences that spinal cord stimulation may have upon the aut-
onomic nervous system. The fact that patients receiving spinal cord stimulation usually describe a
sensation of warmth, especially in the lower limbs, suggested that spinal cord stimulation may alter
blood flow in the skin. Patients with dependent discoulouration due to stagnant hypoxia associated with
poor peripheral circulation in multiple sclerosis show improvement in the colour of dependent
limbs. Friedman⁷ noted a thermographically detect-
able increase in blood flow in the region of analgesia
during spinal cord stimulation for pain. Cook et al⁸
described pain relief and healing of ulcers in nine
patients with vascular insufficiency in the limbs
which in many cases had failed to respond to con-
ventional therapy. These changes could be
repeatedly cycled by starting or stopping stimula-
tion. However, few measurements have been made
of blood flow during spinal cord stimulation. More
detailed studies have been done in the case of trans-
cutaneous stimulation with conflicting results being
reported.⁹-¹²

In view of these observations, and our own
experience of a patient with multiple sclerosis and
arteriographically demonstrated peripheral vascular
insufficiency who reported decreased claudication
pain during the period of spinal cord stimulation,
despite increased mobility, we studied the effects of
spinal cord stimulation upon cutaneous blood flow
in the lower limbs of patients receiving this treat-
ment for chronic neurological disease.

We were able to demonstrate an increase in
cutaneous blood flow in these patients¹³ and there-
fore felt justified in embarking upon a trial of spinal
cord stimulation in peripheral vascular insufficiency.
The purpose of this paper is to present preliminary
observations on 10 such patients who received
epidural spinal cord stimulation. In seven of these
patients this was preceded by a period of trans-

*Present address and address for reprint requests: Dr RC Tallis,
Senior Lecturer in Geriatric Medicine, Royal Liverpool Hospital,
Liverpool, L69 3BX, UK

Received 25 November 1982
Accepted 5 January 1983

478
cutaneous stimulation which we believe acts only as a placebo in this context. In an eighth patient transcutaneous stimulation immediately followed spinal cord stimulation. Two patients received spinal cord stimulation alone.

Methods

Patients:
All patients were referred from the Department of Vascular Surgery at the Royal South Hampshire Hospital where they had been under the care of either Mr J Webster, or Mr AD Chant. In all cases the diagnosis was clear and arteriographically proven, symptoms were severe and disabling and had not responded to conventional surgical and medical therapy. Clinical details of the patients studied are given in Table 1. All patients had been instructed to give up smoking at the onset of their illness and four had complied with this absolutely. Six had been unable to give up smoking entirely but their smoking pattern had been stable for many months prior to the period of stimulation and remained constant throughout this. In particular, the timing of cigarettes in relation to investigations was constant throughout the period of study.

Methods of Assessment
Claudication distance: Claudication distance was measured several times prior to and during each period of stimulation at fixed times of day over a given course at a fixed walking speed. In cases 9 and 10 claudication distance was assessed by means of a treadmill set at 2 km per hour. Severe rest pain prevented complete assessment of case 7.

Exercise tolerance: Exercise tolerance was measured on a bicycle ergometer, the patient being required to maintain 100 watts. The time to the point at which this was no

Table 1 Patients with peripheral vascular disease receiving spinal cord stimulation

<table>
<thead>
<tr>
<th>Case</th>
<th>Age</th>
<th>Sex</th>
<th>Duration of Ischaemic symptoms (yr)</th>
<th>Symptoms at time of spinal cord stimulation</th>
<th>Period for which symptoms had been stable prior to stimulation</th>
<th>Result of last angiogram</th>
<th>Previous treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>67</td>
<td>M</td>
<td>2</td>
<td>Rest pain Claudication Ulcer</td>
<td>5 months</td>
<td>Diffuse atheroma with stenosis in femoral tree</td>
<td>Lumbar sympathectomy</td>
</tr>
<tr>
<td>2</td>
<td>69</td>
<td>M</td>
<td>2</td>
<td>Claudication</td>
<td>1 year</td>
<td>Diffuse atheroma</td>
<td>Diabetic controlled on insulin</td>
</tr>
<tr>
<td>3</td>
<td>69</td>
<td>M</td>
<td>2</td>
<td>Rest pain Claudication</td>
<td>6 months</td>
<td>Superficial femoral arteries blocked</td>
<td>Diffuse disease: surgery not appropriate</td>
</tr>
<tr>
<td>4</td>
<td>34</td>
<td>F</td>
<td>10</td>
<td>Claudication Rest pain Pain right hand</td>
<td>9 months</td>
<td>Severe generalised Buerger's disease</td>
<td>Right femoro-popliteal bypass</td>
</tr>
<tr>
<td>5</td>
<td>77</td>
<td>M</td>
<td>11</td>
<td>Claudication Intermittent rest pain</td>
<td>3 months</td>
<td>Atheroma. Stenosis left common iliac</td>
<td>Left lumbar sympathectomy</td>
</tr>
<tr>
<td>6</td>
<td>71</td>
<td>M</td>
<td>10</td>
<td>Claudication Rest pain Claudication</td>
<td>18 months</td>
<td>Occluded left femoro-popliteal by-pass</td>
<td>Right femoro-popliteal by-pass</td>
</tr>
<tr>
<td>7</td>
<td>62</td>
<td>M</td>
<td>3½</td>
<td>Ulcer Rest pain Claudication</td>
<td>3 months</td>
<td>Atheroma. Occlusion of superficial femorals.</td>
<td>Left femoro-popliteal by-pass</td>
</tr>
<tr>
<td>8</td>
<td>60</td>
<td>M</td>
<td>11</td>
<td>Claudication Nocturnal rest pain</td>
<td>5 months</td>
<td>Occlusion left iliac and superficial femorals.</td>
<td>Aoro-iliac endarterectomy</td>
</tr>
<tr>
<td>9</td>
<td>61</td>
<td>M</td>
<td>13</td>
<td>Claudication</td>
<td>3-4 years</td>
<td>Narrowing of aorta and iliac vessels. Blocked right superficial femoral and popliteal artery.</td>
<td>Right femoropopliteal by-pass</td>
</tr>
<tr>
<td>10</td>
<td>57</td>
<td>M</td>
<td>7</td>
<td>Claudication</td>
<td>4 months</td>
<td>Iliacs blocked. No flow in left popliteal.</td>
<td>Aortic onlay graft.</td>
</tr>
</tbody>
</table>

Notes:
- Age in years.
- Sex: M = Male, F = Female.
- Duration of Ischaemic symptoms: in years (yr).
- Symptoms at time of spinal cord stimulation.
- Period for which symptoms had been stable prior to stimulation.
- Result of last angiogram.
- Previous treatment.
longer possible was recorded. A mean of three measurements was obtained on at least two occasions prior to stimulation and during each period of stimulation. The severity of rest pain prevented this from being measured in cases 1 and 7.

**Cutaneous blood flow:** Cutaneous blood flow after a half hour period of rest with the patient supine was measured in eight patients by clearance of injected xenon 133 dissolved in saline. Sites just below the head of the fibula and on the dorsum of the feet were used. In two patients (cases 7 and 10) rest pain made it impossible to make measurements in both legs so the leg more affected by symptoms was examined. Case 4 had had a mid-thigh amputation of the right leg.

**Muscle blood flow:** This was measured by xenon clearance, the blood flow being recorded in the calf muscles at rest and during exercise with a specially designed standard calf exerciser. Only three out of the 10 patients were able to maintain exercise for a sufficiently long period for a meaningful clearance curve to be obtained (cases 2, 3 and 4). Resting muscle blood flow was recorded in two further patients (cases 6 and 10).

After selection for the trial the patients underwent full assessment. This was repeated on admission to hospital and the following day electrodes were put in place. Seven of the patients had ten days of transcutaneous stimulation and the assessment was repeated. Electrodes were then changed over from transcutaneous stimulation to spinal cord stimulation and after a further ten days of stimulation the assessment was again repeated. In one patient spinal cord stimulation immediately preceded transcutaneous stimulation and in two patients spinal cord stimulation alone was given because they were in a clinically critical state and a ten day delay before spinal cord stimulation could not be ethically justified.

**PROCEDURE:**

**Epidural spinal cord stimulation:** The method of inserting epidural electrodes through an epidural needle for spinal cord stimulation has been described. The electrodes were positioned so that the patient experienced a pleasant tingling sensation extending symmetrically down into the legs when the stimulator was switched on. The stimulator delivers a continuous train of square wave pulses of 200 μs duration at approximately 8 mA and at a frequency of about 33 Hz and was switched on continuously during the period of the trial.

**Transcutaneous Stimulation:** In eight patients the response to spinal cord stimulation was compared with that to a comparable period of transcutaneous stimulation delivered by means of surface electrodes placed over the lumbar spine. It was intended that transcutaneous stimulation should act as a placebo. No indication was given to the patient as to which electrodes would be expected to produce an effect. Nevertheless, it was not possible to carry out a completely blind trial because different stimulator sensations are associated with surface electrodes (local tingling) and epidural electrodes (paraesthesiae and warmth throughout the lower limbs).

**Results**

**CLINICAL RESPONSE TO EPIDURAL SPINAL CORD STIMULATION**

<table>
<thead>
<tr>
<th>Patient</th>
<th>Rest pain*</th>
<th>Claudication distance</th>
<th>Other clinical changes</th>
<th>Subsequent progress</th>
</tr>
</thead>
<tbody>
<tr>
<td>Case 1</td>
<td>++</td>
<td>58 ± 5</td>
<td>320 ± 80</td>
<td>Indolent ulcer healed.</td>
</tr>
<tr>
<td></td>
<td>-</td>
<td>120 ± 21</td>
<td>372 ± 92</td>
<td>Improved colour of foot</td>
</tr>
<tr>
<td>Case 2</td>
<td>++</td>
<td>16 ± 3</td>
<td>366 ± 208</td>
<td>Improved colour of foot</td>
</tr>
<tr>
<td></td>
<td>+</td>
<td>98 ± 22</td>
<td>606 ± 190</td>
<td>Improved colour of foot. Reported restoration of sweating in feet</td>
</tr>
<tr>
<td>Case 3</td>
<td>+</td>
<td>8 ± 2</td>
<td>24 ± 6</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td>-</td>
<td>50 ± 11</td>
<td>83 ± 10</td>
<td>None</td>
</tr>
<tr>
<td>Case 4</td>
<td>++</td>
<td>13 ± 15</td>
<td>12 ± 8</td>
<td>Temporary improvement of colour of foot</td>
</tr>
<tr>
<td></td>
<td>+</td>
<td>133 ± 35</td>
<td>142 ± 12</td>
<td>None</td>
</tr>
<tr>
<td>Case 5</td>
<td>-</td>
<td>100 ± 20</td>
<td>126 ± 25</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td>+</td>
<td>55 ± 7</td>
<td>69 ± 8</td>
<td>None</td>
</tr>
</tbody>
</table>

* Rest pain: (+) Sporadic; (++) Every night; (+++) Day and night; (-) No rest pain.

**Table 2  Clinical response to spinal cord stimulation (SCS)**
Spinal cord stimulation in peripheral vascular disease

Of three patients with indolent ulcers, one healed within a fortnight of stimulation and one was not improved. The third patient (case 5) who had had remarkable relief from rest pain during the period of spinal cord stimulation died of a ruptured aortic aneurysm one week after starting. The duration of his stimulation was too short to allow for healing of ulcers. In four out of seven patients with striking discolouration of the feet, there was an improvement in colour though in one this was only temporary. One patient reported restoration of sweating in the feet. In four out of the ten patients there was a very striking increase in the claudication distance. In two others there was a moderate but significant increase in claudication distance which, in one of these patients, was sufficient to enable him to go shopping with his wife, for the first time for years. In four patients there was no significant change in claudication distance. In one of these patients, although there was no reduction in claudication distance, rest pain and dependent rubor became worse. The mean pre-stimulation claudication distance was 65 ± 45 metres and that during spinal cord stimulation was 212 ± 147 metres. This difference was significant (0·025 > p > 0·01).

CLINICAL RESPONSE TO TRANSCUTANEOUS STIMULATION
Seven patients received transcutaneous stimulation before going on to epidural stimulation of the spinal cord. None of these patients showed any clinical improvement during a two week period of transcutaneous stimulation. Assessment of their claudication distance and exercise tolerance on the bicycle ergometer showed no change from the pre-stimulation state.

EXERCISE ENDURANCE ON THE BICYCLE ERGOMETER
Exercise tolerance increased from 3929 ± 1961 joules to 6328 ± 3421 joules (61% increase) but this was not statistically significant (0·10 > p > 0·05).

BLOOD FLOW STUDIES (tables 3 and 4)
Skin blood flow was measured in eight out of the ten patients who responded clinically. Skin blood flow measurements were made at two sites on each leg. For a variety of reasons blood flow studies on the right legs are incomplete and only the results for the left legs and feet are given. There was a significant

<table>
<thead>
<tr>
<th>Test</th>
<th>Units</th>
<th>n</th>
<th>Before</th>
<th>SCS</th>
<th>p*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Skin blood flow:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Left foot</td>
<td>ml/min/100G</td>
<td>4</td>
<td>5-45 ± 1-13</td>
<td>6-90 ± 1-64</td>
<td>0·02</td>
</tr>
<tr>
<td>Left leg</td>
<td>ml/min/100G</td>
<td>4</td>
<td>3-33 ± 1-86</td>
<td>3-23 ± 0-70</td>
<td>NS</td>
</tr>
<tr>
<td>Muscle blood flow:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rest</td>
<td>ml/min/100G</td>
<td>4</td>
<td>1-10 ± 0-68</td>
<td>2-20 ± 1-13</td>
<td>0·05</td>
</tr>
<tr>
<td>Exercise</td>
<td>ml/min/100G</td>
<td>4</td>
<td>3-68 ± 1-64</td>
<td>5-24 ± 2-93</td>
<td>NS</td>
</tr>
</tbody>
</table>

*p calculated by paired t test

<table>
<thead>
<tr>
<th>Test</th>
<th>Units</th>
<th>n</th>
<th>Before</th>
<th>SCS</th>
<th>p*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Skin blood flow:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Left foot</td>
<td>ml/min/100G</td>
<td>4</td>
<td>2-40 ± 3-50</td>
<td>1-68 ± 1-71</td>
<td>NS</td>
</tr>
<tr>
<td>Left Leg</td>
<td>ml/min/100G</td>
<td>4</td>
<td>1-33 ± 0-40</td>
<td>1-38 ± 1-31</td>
<td>NS</td>
</tr>
<tr>
<td>Muscle blood flow:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rest</td>
<td>ml/min/100G</td>
<td>1</td>
<td>1-2</td>
<td>1-2</td>
<td>NS</td>
</tr>
<tr>
<td>Exercise</td>
<td>ml/min/100G</td>
<td>—</td>
<td>Not done</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*p calculated by paired t test

Table 3 Effect of spinal cord stimulation (SCS) on blood flow in peripheral vascular disease
Patients responding
Mean and standard deviation given

Table 4 Effect of spinal cord stimulation (SCS) on blood flow in peripheral vascular disease
Non-responders
Mean and standard deviation given
increase in blood flow in the left foot of the clinically responding patients but not at the site on the left legs just below the head of the fibula. The non-responders showed no significant change in blood flow.

Muscle blood flow at rest and during exercise was measured in four of the responding patients but only incomplete studies in one of the non-responders are available. Of the responding patients there was a statistically significant doubling of muscle blood flow at rest. During exercise an increase in blood flow was recorded but this did not reach statistical significance. Only one non-responding patient was studied and showed no change at rest.

In summary, those patients who had a favourable clinical response also showed an improvement in four of the six objective tests of exercise tolerance and blood flow, while of the patients who did not respond clinically there were no changes in the assessment tests with the exception of the bicycle ergometer test where there was a slight deterioration in performance. We conclude that the clinical improvement seen in these patients cannot be attributed to a placebo response but it is probable that some beneficial physiological change occurred in the peripheral vascular system.

Discussion

The patients selected for spinal cord stimulation all had severe symptoms and had either failed to respond to conventional surgical and medical treatment or were unsuitable for such treatment. Five out of ten patients had a sufficiently marked clinical response to justify permanent stimulation. A sixth patient had a good response but died suddenly of a ruptured aortic aneurysm in the epidural stimulation period. It was possible to demonstrate moderate increases in skin and/or muscle blood flow and these were statistically significant in the skin of the foot and in the case of resting muscle blood flow. Muscle blood flow during exercise showed an increase which did not reach statistical significance.

In all the patients the improvements obtained initially were maintained as long as permanent stimulation could be continued. In two of the patients receiving permanent stimulation, spinal cord stimulation had to be discontinued for technical reasons and both deteriorated clinically. Repair of the spinal cord stimulation system so that a stimulator sensation was once more obtained in the legs at once restored the improvement that had been obtained. In one patient receiving permanent stimulation, who had developed gangrene in the hand, an area not being stimulated at the time, insertion of electrodes to produce a stimulator sensation in the hand did not reverse the gangrene. This experience is consistent with Cook's observation that once gangrene has set in, spinal cord stimulation has little to offer.

In interpreting the response to a new form of treatment one must take into account the natural history of the disease and the possibility of placebo effect. It is well known that intermittent claudication tends to improve with time but this usually occurs over a period of months rather than days, and moreover tends to occur in the early stages of the illness. It is usual for patients with severe persistent rest pain to remain stable or to get worse.

Transcutaneous stimulation might reasonably have been expected to produce similar symptomatic relief if the patients were responding to a placebo effect. Both spinal cord stimulation and transcutaneous stimulation techniques involved electrodes, wires and stimulator controls and both produced a sensation. Care was taken to ensure that the patients could not infer which method was supposed to work. Measurement of current in the epidural space during transcutaneous stimulation showed it to be less than with spinal cord stimulation by a factor of 2,000. It would therefore appear impossible to stimulate the spinal cord by transcutaneous stimulation using the currents and voltages available. No symptomatic or objectively measured improvement occurred with transcutaneous stimulation. The duration of the improvement seen and its dependency upon continuing spinal cord stimulation is against a placebo effect. The improvements noted in blood flow and the other objectively measured changes make a placebo effect less likely.

Our findings with transcutaneous stimulation are contrary to those of Canosa et al who reported improvement in patients with peripheral vascular disease during transcutaneous stimulation over a three month period.

MECHANISMS

Several mechanisms may be invoked to account for the improvements seen:

1. Pain relief: Pain relief, a well documented effect of spinal cord stimulation, may release the reflex vasoconstriction that is known to occur in response to pain. This might break a vicious circle by which pain leads to vasoconstriction and vasoconstriction leads to further pain.

2. Sympathetic nervous system: Very small changes in blood flow may be critical in determining whether skin is viable and also in influencing claudication distance. The xenon clearance method of blood flow measurement has well known sources of error and variation and must, at best, be considered a rather insensitive measure of detecting clinically significant alterations in circulation. However, a statistically
significant increase in muscle blood flow and in skin blood flow of the foot, but not of the lower leg, was detected in response to spinal cord stimulation. If the clinical improvement is due to increased blood flow, as well as to pain control, then it seems unlikely that the sympathetic nervous system should be involved. Whereas inhibition of alpha adrenergic vasconstrictor fibres and stimulation of cholinergic vasodilator fibres will produce respectively increased blood flow in the skin and in the muscles, it is unlikely that spinal cord stimulation will produce this balanced combination of effects.

3. Prostaglandins and prostacyclins: Bayliss demonstrated that stimulation of the dorsal roots produced hind limb vasodilatation in the cat and Foerster showed that dorsal root stimulation in man produced vasodilatation in the appropriate dermatome. Recently Hilton and Marshall have demonstrated vasodilatation in the muscles following dorsal root stimulation and they believe that this effect is due to antidromic stimulation of small diameter fibres. Interestingly, it could not be blocked by sympathetic blocking agents but could be blocked by prostaglandin inhibitors from which they inferred that it was mediated by the release of prostaglandins in muscles. Whether these fibres are involved in the effects seen in ischaemic patients receiving spinal cord stimulation is not certain. There is no doubt, however, that spinal cord stimulation involves stimulation of the central processes of the first order sensory neurons and that there is no reason why these should not be stimulated antidromically as well as orthodromically.

4. Local vascular control: There may be some difficulty in understanding how neural modulation could overcome the essentially structural problem that occurs in obliterative arterial disease. There is, however, some evidence that physiological responses to arterial insufficiency may not be optimal. As noted above, reflex vasoconstriction occurs in response to pain and structural changes in the arterial wall may cause augmentation of vasoconstrictor responses to adrenergic stimuli. The intra-articular infusion of alpha-adrenergic blockers such as thyromoxime may produce marked improvement in the pulse plethysmograph in patients with severe peripheral vascular disease. Recently it has been shown that intra-articular prostacyclin infusion may produce dramatic increases in blood flow associated with marked clinical improvement. This effect has been attributed to reduction in platelet coagulation, vasodilatation and in some cases the induction of the proliferation of small vessels. At the very least, it does indicate that even in obstructive arterial disease there is a residual neuropharmacological reserve that may be exploited. It is possible that neurally mediated release of prostacyclins resulting from antidromic stimulation of sensory neurons could produce this effect.

It has been argued that a generalised vasodilatation would have an adverse effect on patients with severe arterial disease, increased blood flow being directed towards unobstructed arteries so that blood flow distal to the site of obstruction falls even further. If, however, the ony effect of spinal cord stimulation is to reverse adverse physiological changes that occur locally distal to the site of a block, then of course vasodilatation would occur only in those places where it was required and not elsewhere where it may lead to further diminution of blood flow in ischaemic areas.

This work is still at a very early stage. The results that we have obtained so far, both in terms of clinical response and objective measures of claudication and exercise tolerance, as well as some of the changes seen in blood flow, suggest that spinal cord stimulation may have a part to play in the management of advanced arterial disease where all other forms of treatment have failed. Clearly this will represent only a small group of patients and this group will be even smaller if sufferers from vascular disease were able to resist the urge to smoke. Moreover, spinal cord stimulation will have no influence upon the underlying pathology and cannot be expected to reverse gangrene. In view of the encouraging results a larger trial is underway in order to clarify the indications for spinal cord stimulation and to investigate the mechanisms involved.

We are very grateful to Mr J Webster, FRCS and Mr AD Chant, FRCS of the Department of Vascular Surgery at the Royal South Hampshire Hospital for kindly referring patients. We are also grateful to Mr CAC Clyne for useful advice at many stages of the present project. Finally, we thank Miss Gillian Green for typing the manuscript.

References


Spinal cord stimulation in peripheral vascular disease.

R C Tallis, L S Illis, E M Sedgwick, C Hardwidge and J S Garfield

*J Neurol Neurosurg Psychiatry* 1983 46: 478-484
doi: 10.1136/jnnp.46.6.478

Updated information and services can be found at:
http://jnnp.bmj.com/content/46/6/478

**Email alerting service**

These include:

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/